Company / Shareholders' Equity
Candel Therapeutics, Inc. Shareholders' Equity History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$12.7M
FY2023
5-year range
-$23.6M / $64.1M
FY2021-FY2023
Trend
-80.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$24M to $13M over the past 2 years.
Based on SEC 10-K filings.
$13M in FY2023.
Improved from -$24M to $13M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, shareholders' equity decreased 80.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $12.7M | -80.1% |
| FY2022 | $64.1M | +372.2% |
| FY2021 | -$23.6M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026